About ChanTest
ChanTest is a Healthcare company based in Cleveland (United States) founded in 1998, and was acquired by Charles River Laboratories in October 2014. Ion channel safety testing and screening services are provided. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In Vitro Assays. Its competitors include Anabios, Quiver Bioscience and Zen-Bio; 1 of its 3 listed competitors has raised funding.
Company details
ChanTest was established in 1998 in Cleveland, United States, as a contract research organization specializing in ion channel and GPCR assays. GLP and non-GLP services, including reagents, validated cell lines, and pre-clinical cardiac risk assessments, were offered to pharmaceutical and biotech firms. Compounds for over 300 companies were tested. Applied Cell Sciences was acquired in 2009, and the company was purchased by Charles River in 2014 for 54 million.
- Headquarters Cleveland, United States
- Stage Acquired
- SectorsHealthcare
- Website chantest.com
- Social LinkedIn X Facebook
- Acquired by Charles River Laboratories (Oct 2014)
- Latest Funding Round$1M (USD), Grant
Sep 2012
- InvestorsCharles River Laboratories
& 2 more
- Acquired byCharles River Laboratories
(Oct 2014)
Funding Insights of ChanTest
- Total Rounds 3
- Last Round Grant — $1M
- Investors Count 2
All 3 funding rounds of ChanTest with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2012 | $1M | Grant | – | – | |
| May 2009 | $4.8M | Grant | – | – | – |
| Aug 2007 | Private Equity Round | – | – |
3 investors in total: 3 institutional.
Investors in ChanTest
ChanTest has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Charles River Laboratories, NIH SBIR/STTR and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sbir.nih.gov | ||||
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States | ||
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States |
Investor details for ChanTest
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ChanTest
4 dated milestones of ChanTest across 16 years, from founding to its latest funding, stage changes and deals.
- Founded ChanTest is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $1.0M.
- Exit Acquired by Charles River Laboratories.
Competitors of ChanTest
ChanTest has 3 listed competitors in our database, 1 of them funded. They include Anabios, Quiver Bioscience and Zen-Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| anabios.com | 2009 | San Diego, United States | $24.78M | 51 | Ex-vivo human tissue studies are performed for preclinical drug discovery. | |
| quiverbioscience.com | 2013 | Cambridge, United States | Developer of transformational medicines for neurological disorders | |||
| zen-bio.com | 1995 | Durham, United States | Cell-based solutions are provided to accelerate therapy discovery and development. |
Detailed competitors of ChanTest
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as ChanTest (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ChanTest
ChanTest was founded in 1998 and raised its 1st funding round 9 years after it was founded.
ChanTest is headquartered in Cleveland, United States. It is registered at Cleveland, Ohio, United States.
ChanTest was established in 1998 in Cleveland, United States, as a contract research organization specializing in ion channel and GPCR assays. GLP and non-GLP services, including reagents, validated cell lines, and pre-clinical cardiac risk assessments, were offered to pharmaceutical and biotech firms. Compounds for over 300 companies were tested. Applied Cell Sciences was acquired in 2009, and the company was purchased by Charles River in 2014 for 54 million.
ChanTest's top competitors include Quiver Bioscience, Anabios and Zen-Bio.
ChanTest has 3 investors. Key investors include Charles River Laboratories, NIH SBIR/STTR, and Ampersand Capital Partners.
Yes. ChanTest was acquired by Charles River Laboratories in October 2014.